Plain-English translation of NCT07140484 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a medication called to see if it can help people with pulmonary arterial hypertension (a condition where blood vessels in the lungs become narrow and stiff) improve their blood vessel function and overall exercise ability. You would need to already be taking at least two other PAH medications to join this study. The research team will measure how well the new medication works alongside your current treatments.
Pulmonary arterial hypertension is a serious condition that limits how much people can exercise and function in daily life, even with current treatments. This study is exploring whether the medication can help blood vessels work better and improve symptoms in people who are already on standard PAH therapies.
You likely qualify if…
You likely don't qualify if…
You would start with three screening visits over two weeks where doctors will review your health history, run blood tests, do heart imaging, and measure how far you can walk and how well your lungs work. Then you would receive injections of the medication and come back for follow-up visits over several months—some at your local site and some in Edmonton—where the research team will repeat tests to see if the medication is helping your blood vessels and your ability to exercise.
AI-generated summary from trial data · Jul 13, 2026 · Not medical advice
Canada